1. Capital Increase Form (F 53-4) 2. Information Memorandum concerning the Offering and Allocation of the Newly Issued Shares of Hydrotek Public Company Limited 3. Information Memorandum concerning

subsidiaries for 1Q21 at Baht 1,463 million, an increase of 32.0% from the previous quarter. When comparing to 1Q20, net profit decline slightly by 1.4%. The consolidated comprehensive income for 1Q21 totaled

(BGRIM) at “A” with “stable” outlook. The rating reflects the company’s position as one of the leading private power producers in Thailand, its well-diversified portfolio of cogeneration power units under

revenue from sale for Q1/2018 ended March 31, 2018 of Baht 81.01 million, compare with the same period of previous year amount to Baht 73.98 million which increase Baht 7.02 million or 9.49%, which main

totaled Baht 1,386 million, an increase of 21.2% yoy from the growth in deposit consistent with the overall expansion in loan portfolio. Cost of funds for 1Q19 remained stable at 2.3% comparing to 1Q18. For

17.74% 20.03 9.21% 49.42 246.73% Jul – Sep 63 Jul – Sep 62 Increase/(Decrease) DOD BIOTECH PUBLIC COMPANY LIMITED เลขที่ 111 หมู่ที่ 2 ตาํบลท่าจนี อาํเภอเมืองสมุทรสาคร จงัหวดัสมุทรสาคร 74000 111 Moo 2

Bt117,244mn following the economic environment and competition, offset by the significant increase in subscriber base with a net addition of 2.68mn. The strong net additions were driven by our strong

which will be due in 2021-2024. 6. Benefits which the Company will receive from the capital increase/share allotment The capital increase will result in a stronger and more stable financial structure, in

stable and will moving in the same trend as in Q4/17. We strongly believe that we can increase production capacity and also maintain the metal spread to strengthen the Company business. 2. Business Outlook

 In Q4/2017, the Company and its subsidiary recorded total sales of Baht 1,531 million, an increase of 2% YoY, following growth from domestic CMG launching new products as well as continue growth from